111 Inc (YI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, 111 Inc (YI) has a cash flow conversion efficiency ratio of 0.139x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($29.87 Million) by net assets ($214.56 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 111 Inc net asset quality index to measure how much of total assets are equity-financed.
111 Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how 111 Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 111 Inc cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
111 Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of 111 Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Control Bionics Ltd
AU:CBL
|
-0.288x |
|
Clean Seas Seafood Ltd
AU:CSS
|
0.194x |
|
Japan Gold Corp
V:JG
|
-0.051x |
|
Artmarket.com SA
PA:PRC
|
0.031x |
|
Gotland Rederi AB Series B
ST:GOTL-B
|
-0.015x |
|
Everbright Digital Holding Limited Ordinary Shares
NASDAQ:EDHL
|
N/A |
|
Skye Bioscience, Inc. Common Stock
NASDAQ:SKYE
|
-0.950x |
|
Han Express
KO:014130
|
0.053x |
Annual Cash Flow Conversion Efficiency for 111 Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of 111 Inc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see YI stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $214.56 Million | $119.14 Million | 0.555x | -19.61% |
| 2024-12-31 | $380.76 Million | $263.02 Million | 0.691x | +142.64% |
| 2023-12-31 | $276.10 Million | $-447.24 Million | -1.620x | -4435.40% |
| 2022-12-31 | $648.24 Million | $-23.15 Million | -0.036x | +95.28% |
| 2021-12-31 | $848.71 Million | $-641.94 Million | -0.756x | -761.87% |
| 2020-12-31 | $1.33 Billion | $-116.78 Million | -0.088x | +86.69% |
| 2019-12-31 | $773.92 Million | $-510.19 Million | -0.659x | -135.19% |
| 2018-12-31 | $1.22 Billion | $-343.02 Million | -0.280x | +56.27% |
| 2017-12-31 | $318.82 Million | $-204.37 Million | -0.641x | +5.07% |
| 2016-12-31 | $575.52 Million | $-388.65 Million | -0.675x | -- |
About 111 Inc
111, Inc., together with its subsidiaries, operates an integrated online and offline platform in the healthcare market in the People's Republic of China. It operates through two segments, B2C and B2B. The company offers supply chain integration services that help pharmaceutical companies manage products through online and offline channels; product promotion, customer analytics, patient education,… Read more